$ATNM

Actinium Pharmaceuticals, Inc. (ATNM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer NEW YORK, October 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (“Actinium” or the “Company”), a pioneer in the develo

Actinium Pharmaceuticals presented early Phase 1 trial data for ATNM-400, a non-PSMA targeted radiotherapy for metastatic castration-resistant prostate cancer (mCRPC). The study aims to assess safety, biodistribution, and dosimetry of Zirconium-89-labeled ATNM-400, with plans to advance to Actinium-225-labeled therapy. According to the company, ATNM-400 targets a novel antigen and could benefit a broad mCRPC patient population, including those resistant to PSMA-directed therapies.

Actinium Pharmaceuticals (ATNM) named Matt David as its new CFO. David has over 20 years of experience in biopharma and healthcare finance. ATNM shares rose 2% in pre-market trading.

Actinium Pharmaceuticals (NYSE American: ATNM) said it expanded Actimab-A intellectual property with multiple newly issued US patents and additional pre-grant/allowed applications, covering uses in AML, MDS, and solid tumors, including combinations with venetoclax and CLAG-M. The company also amended its IND to add a manufacturing source and reported NYSE American listing compliance plan acceptance through Nov. 27, 2027.

Actinium Pharmaceuticals said the Canadian Intellectual Property Office issued Notices of Allowance for two patent applications covering its Actimab-A and Iomab-ACT programs. The Actimab-A/CLAG-M AML combination allowance is expected to issue with a term into Jan. 2039; the CD45 conditioning for gene-edited cell therapies is expected to issue with a term into Oct. 2038. Actinium said this adds to a global portfolio of about 250 issued and pending patents.

Actinium Pharmaceuticals (NYSE American: ATNM) said it will present new ATNM-400 (Actinium-225 antibody radioconjugate) data at SNMMI 2026 in Los Angeles May 30–June 2, with three posters on prostate cancer, NSCLC, and radioconjugate optimization. Separately, NYSE American notified the company it is not in compliance with $4.0m stockholders’ equity requirements; Actinium must submit a compliance plan by June 26, 2026.

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Here is how Actinium Pharmaceuticals (ATNM) and Avadel (AVDL) have performed compared to their sector so far this year.

NEW YORK, June 10, 2025 ( GLOBE NEWSWIRE ) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research.

NEW YORK, May 25, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. ATNM between October 31, 2022 and August 2, 2024, both dates inclusive ( the "Class Period" ) , of the important May 27, 2025 ...